Patients and data collection
This was a multi-center retrospective study. All patients diagnosed with
NECC who were subjected to surgery at the three Gynecologic Oncology
Departments, namely, the Xijing Hospital of the Fourth Military Medical
University, Northwest Women’s and Children’s Hospital, and General
Hospital of Western Theater Command of PLA in China between 2009 and
2022 were recruited. All clinical and pathological data were recorded,
including age, FIGO stage (2018), tumor size, gestational history,
history of illness, family history, treatment strategy, histological
type, uterus invasion, depth of stromal invasion, lymphovascular
invasion (LVSI), surgical margins, lymph node metastasis, and perineural
invasive. All follow-up data were collected by telephone and from
outpatient clinical records until July 28, 2022. Patients who did not
undergo surgery were excluded. A total of 58 eligible patients were
included. This study was approved by the Ethics Committee of the Xijing
Hospital of the Fourth Military Medical University (KY20222112-C-1) and
completed registration at the Chinese Clinical Trial Registry
(ChiCTR2200063023).